Organizing Committee
OCM Member
AVM Biotechnology , USA
Biography :

Theresa A. Deisher obtained her Ph.D. in Molecular and Cellular Physiology from Stanford University School of Medicine. An expert in adult stem cell research, she is the first person to discover adult pluripotent stem cells. She is an inventor of over 35 issued US/Japan patents, whose discoveries have led to clinical trials of fibroblast growth factor 18 for osteoarthritis and cartilage repair, and for Factor XIII for surgical bleeding. Prior to founding AVM Biotechnology, she worked at leading biotechnology companies including Genentech, Repligen, ZymoGenetics, Immunex and Amgen as their principal scientist and R&D Vice President. She has had extensive scientific and management experience in the commercial biotechnology field, including: • Genentech 1988-1990 • Repligen 1993-1995 – Hematopoietic Stem Cell Chemoattractants • ZymoGenetics 1995-2000 – Adult Cardiac Stem Cell; Mesodermal – Derived Stem Cell; VSEL Very Small Embryonic-Like Stem • Immunex/Amgen 2000-2006 – Derivation of Embryonic-Like Stem Cells from Human Cord Blood. She is a frequent lecturer on stem cell issues and an active member of ASH (The American Society of Hematology) and ASCO (ASCO: American Society of Clinical Oncology)

Research Interest :

Stem Cell Research

OCM Member
University of Rochester , USA
Biography :

Henry M. Sobell completed his studies at Brooklyn Technical High School (1948-1952), Columbia College (1952-1956), and the University of Virginia School of Medicine (1956-1960). Instead of practicing clinical medicine, he then went to the Massachusetts Institute of Technology (MIT) to join Professor Alexander Rich in the Department of Biology (1960-1965), where, as a Helen Hay Whitney Postdoctoral Fellow, he learned the technique of single crystal X-ray analysis. He then joined the Chemistry Department at the University of Rochester, having been subsequently jointly appointed to both the Chemistry and Molecular Biophysics departments (the latter at the University of Rochester School of Medicine and Dentistry), becoming a full tenured Professor in both departments (1965-1993).He is now retired and living in the Adirondacks in New York, USA.

OCM Member
cellcopedia , Germany
Biography :

Wilhelm Gerdes has completed his PhD from Eberhard-Karls-Universit ät Tübingen, Germany. He was CBO of CellCopedia GmbH. He was CFO of Magna Diagnostics. At present he is working as a BDM at IBA Lifesciences

Research Interest :

Stem Cell Research

OCM Member
The University of Texas , USA
Biography :

Finished postdoctoral training at Baylor College of Medicine (Immunology) and Harvard Medical School (Translational Cancer Research),presently working at Department of Immunology at MD Anderson focusing on tumor immunology.

OCM Member
University of Manchester , United Kingdom
Biography :

Damian Marshall is the head of analytical development for the Cell and Gene Therapy Catapult and has almost 20 years of industrial gained working for SME’s and large companies. He leads a team of ~30 scientists working with a wide range of therapy developers helping to de-risk their route to commercialisation. This is achieved through advanced product characterisation, helping companies to manage sources of variability and gain a high level of products and process knowledge. His team is also supporting the development of new adaptive manufacturing approaches by integrating technologies to allow real-time product monitoring and enable feedback control during product manufacture.

Research Interest :

Stem Cell Research

OCM Member
Federal University of Minas Gerais , Brazil
Biography :

Dr. Alexander Birbrair started his scientific career from B.S. in Biomedical Sciences from Universidade Estadual de Santa Cruz, UESC, Ilheus, Brazil. He completed his Ph.D. in Neurosciences Program, particularly in the field of Stem Cell Biology, from Wake Forest School of Medicine, Winston-Salem, NC, USA. Dr. Birbrair received his Post-Doctoral Degree from Albert Einstein College of Medicine, Bronx, NY, USA in Stem Cell Biology and joined as a Professor at Department of Pathology, Federal University of Minas Gerais, Belo Horizonte, MG, Brazil in 2016. He is a recipient of several notable awards and honours, which includes, Gordon A. Melson Outstanding Doctoral Student Award for 2015 and Editor's choice Award in Journal of Gerontology Biological Sciences Volume 69 Issue 12 December 2014 for the manuscript “Human Slow Troponin T (TNNT1) Pre-mRNA Alternative Splicing is An Indicator of Skeletal Muscle Response to Resistance Exercise in Older Adults.” by Zhang T, Choi SJ, Wang ZM, Birbrair A, Messi ML, Jin J-P, Marsh AP, Nicklas B, and Delbono O. He is an active member of American Heart Association, Western NC Chapter of the Society for Neuroscience and International Society for Stem Cell Research with more than 30 publications in peer-reviewed journals and serves as an ad hoc reviewer for 14 Journals related to pathology and stem cell biology.

Research Interest :

Stem Cell Research

OCM Member
Vita-Salute San Raffaele University of Milan , Italy
Biography :

MD cum laude (1962), Assistant and then Associate Professor at the University of Milan (1965-1980), he has been post-doc in the lab of the Nobel Graduate George E. Palade at the Rockefeller University of New York (1968-1970). Professor of General Pharmacology at the University of Milan (1981-1999) and then at the Vita-Salute San Raffaele University of Milan, he is an Emeritus since November 2010.

Research Interest :

Stem Cell Research

OCM Member
University of Stransbourg , France
Biography :

Dr. Nadia Benkirane is Research director and head of the “ Osteoarticular and Dental regenerative Nanomedicine” laboratory, at INSERM (French National Institute for Health and Medical Research), UMR 1109, Strasbourg, France. She was leader of “Active Biomaterials and Tissue Engineering” team INSERM 977. She received her Ph.D. from University Louis Pasteur, ULP, Strasbourg, France for the work on Development of pseudopeptides as synthetic vaccines. Dr. Jessel (Benkirane) then held a postdoctoral position in collaboration with the Institut Pasteur, Paris, France, working on Immunotherapy HIV, and another postdoctoral position on the application of modified peptides as vaccines against FMDV (Plum Island Animal Disease Center, ARS, USDA, Greenport, NY 11944-0848, USA). She joined the INSERM U595 in 2002 as a post-doc, and received the diploma to direct the research (HDR) in 2004. Dr. Jessel got the permanent position (CR1) in the INSERM 595 laboratory in 2004 and Research Director (DR2) position in the INSERM 977 and head of “active Biomaterials and Tissue Engineering team from 2009 until 2012). Currently Research Director (DR1) in the INSERM UMR 1109 (Osteoarticular and Dental Regenerative Nanomedicine" and heads the team. Dr. Jessel possesses expertise in diverse fields of molecular and cellular biology, immunochemistry, tissue engineering and biomedical engineering. In the last 10 years, she focused her research on the bio-functionalization of multilayered polyelectrolyte architectures with emphasis on the use of these architectures to induce specific cellular responses and gain control over cell proliferation and differentiation. Dr. Benkirane-Jessel have 138 publications (h index: 36) with peer-reviewed publications in high impact factor journals (Proc. Nat. Acad. Sci. USA; Adv. Mater.; Adv. Funct. Mater.; Small; Nanoletters, Biomaterials, ACS Nano), 5 chapters reviews and 5 international patents, she is a regular referee for a number of scientific journals (Nature nanotechnology, Nature Materials, ACS nano, Biomaterials, Nanoletters…). She is under the contract (Interface INSERM/Clinic 2008-2013) and she got also “Prime d’Excellence Scientifique” from the INSERM, 2010-2014 and the PEDR from the INSERM on 2016 for 4 years.

Research Interest :

Stem Cell Research

Allied Academies Global Conference Directory

Mail us at

Program Enquiry
genetherapy@alliedscholars.com
Sponsorship opportunity
diana-collins@alliedscholars.net
General Enquiry
celltherapy@alliedscholars.net
More details about sponsorship:sponsors@alliedacademies.com

Terms and Conditions

Responsibility

The organizers holds no responsibilities or liabilities of the personal articles of attendees at the venue against any kind of theft, lost, damage, due to any reason whatsoever. Delegates are entirely responsible for the safety of their own belongings.

 

Insurance

No insurance, of any kind, is included along with the registration in any of the events of the organization.

 

Transportation

Please note that transportation and parking is the responsibility of the registrant, Allied Academies will not be liable for any actions howsoever related to transportation and parking.

 

Press/Media

Press permission must be obtained from Allied Academies Conference Organizing Committee prior to the event. The press will not quote speakers or delegates unless they have obtained their approval in writing. The Allied Academies is an objective third-party nonprofit organization and this conference is not associated with any commercial meeting company.

 

Requesting an Invitation Letter

For security purposes, letter of invitation will be sent only to those individuals who had registered for the conference after payment of complete registration fee. Once registration is complete, please contact celltherapy@alliedscholars.net to request for a personalized letter of invitation, if not received until one month before the scheduled date of event.

All the bank charges applicable during refund will be deducted from the account of participant.

 

Cancellation Policy

All cancellations or modifications of registration must be made in writing to finance@alliedacademies.com

 

Postponement of event

If, due to any reason, Allied academies postpone an event and the participant is unable or unwilling to attend the conference on rescheduled dates, he/she is eligible for a credit of 100% of the registration fee paid. This credit shall only be used for another event organized by Allied academies within period of one year from the date of rescheduling.

 

Transfer of registration

All registrations, after payment of complete registration fee, are transferable to other persons from the same organization, if in case the person is unable to attend the event. Request for transfer of registration must be made by the registered person in writing to contact@alliedacademies.com . Details must include the full name of replaced new registrant, their title, contact phone number and email address. All other registration details will be assigned to the new person unless otherwise specified.

Registration can be transferred to one conference to another conference of Allied academies if the person is unable to attend one of conferences.

However, Registration cannot be transferred if intimated within 14 days of respective conference.

The transferred registrations will not be eligible for Refund.

This cancellation policy was last updated on April 04, 2015.

 

 

Visa Information

Keeping in view of increased security measures, we would like to request all the participants to apply for Visa as soon as possible.

Allied academies will not directly contact embassies and consulates on behalf of visa applicants. All delegates or invitees should apply for Business Visa only.

Important note for failed visa applications: Visa issues are not covered under the cancellation policy of Allied academies, including the inability to obtain a visa.

 

Refund Policy:

If the registrant is unable to attend, and is not in a position to transfer his/her participation to another person or event, then the following refund policies apply:

Keeping in view of advance payments towards Venue, Printing, Shipping, Hotels and other overhead charges, following Refund Policy Orders are available:

  • Before 60 days of the conference: Eligible for Full Refund after deduction of $100 towards service Fee.
  • Within 60-30 days of Conference: Eligible for 50% of payment Refund
  • Within 30 days of Conference: Not eligible for Refund
  • E-Poster Payments will not be refunded.

 

Accommodation Cancellation Policy:

Accommodation Service Providers (Hotels) have their own cancellation policies which are applicable when cancellations are made less than 30 days prior to arrival. If in case the registrant wishes to cancel or amend the accommodation, he/ she is expected to inform the organizing authorities on a prior basis. Allied academies will advise the registrant to ensure complete awareness about the cancellation policy of your accommodation provider, prior to cancellation or modification of their booking.

 

Authorization Policy

Copyright © 2018-2019 Allied Academies, All Rights Reserved.